Subsequently we evaluated the efficacy of a spliceosome inhibitor, Pladienolide B, and found that the drug was effective in all SCLC cell lines (IC50 < 12nM) irrespective of the MYC protein expression or MYC gene amplification status. This evidence concerns the gene MYC and small cell lung carcinoma.